Below is a view of KaloBios’ pipeline. It contains first or best-in-class antibody therapeutic candidates for pulmonary and oncology.
KaloBios Antibody Pipeline
Disclaimer: The information contained above concerns biologics that are under pre-clinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.